Welcome to our dedicated page for Lantern Pharma news (Ticker: LTRN), a resource for investors and traders seeking the latest updates and insights on Lantern Pharma stock.
Lantern Pharma Inc. (Symbol: LTRN) is at the forefront of innovation in the realm of cancer treatment, striving to deliver the most effective therapies to patients who are poised to benefit the most. The company employs a pioneering precision medicine approach to cancer treatment, leveraging biomarker-based genetic screening to identify and treat patients who would derive the greatest benefit from their drugs. This method not only reduces the cost of drug development but also expedites the time to market.
Lantern Pharma's core business revolves around its proprietary artificial intelligence (AI) and machine learning (ML) platform, RADR. The RADR platform assimilates oncology-focused data points and utilizes advanced ML algorithms to address complex, billion-dollar challenges in cancer drug development. This innovative platform has significantly accelerated the company's growing pipeline of precision therapies, with input from world-class scientific advisors and collaborators.
In addition to its in-house development, Lantern Pharma adopts a strategic approach by acquiring or partnering with promising drug and diagnostic companies. This strategy is aimed at advancing personalized medicine programs for cancer patients, thus broadening the company's impact in the oncology space.
With a commitment to transforming the cost, pace, and timeline of oncology drug discovery and development, Lantern Pharma continues to make strides in the development of precision therapies. The company's recent achievements and ongoing projects underscore its potential to revolutionize cancer treatment and deliver significant value to both patients and stakeholders.
Lantern Pharma (LTRN) announced that its abstract on LP-284 has been accepted for presentation at the 63rd American Society of Hematology (ASH) Annual Meeting from December 11-14, 2021. This study focuses on LP-284's effectiveness in treating hematologic cancers. The drug shows promise as a synthetic analogue of LP-184, specifically targeting blood cancers. The poster presentation will occur on December 13, 2021, with Dr. Jianli Zhou as the presenter. Lantern aims to leverage its RADR® platform to optimize patient responses to its therapies.
Lantern Pharma (LTRN) reported significant advancements in its oncology pipeline and financial stability in its Q3 2021 update. The company boasts over $73.8 million in cash and marketable securities, a notable increase from $19.2 million at year-end 2020. Key highlights include the FDA granting Orphan Drug Designation for its LP-184 in glioblastoma and pancreatic cancer, as well as achieving over 10 billion data points in its RADR® AI platform.
Effective preclinical results for LP-184 were also shared, supporting further development and potential therapeutic collaborations.
Lantern Pharma (LTRN) announced that its RADR® A.I. platform has surpassed 10.4 billion datapoints, enhancing its capabilities in oncology drug discovery. This integrated platform offers mechanistic insights into drug-tumor interactions, optimizing drug development strategies and accelerating the identification of effective cancer therapies. Key advancements include new data sources from glioblastoma and pancreatic cancer, alongside improved algorithms to analyze complex datasets quickly. Lantern aims to leverage RADR® for innovative drug-candidate discoveries, ultimately seeking to improve clinical outcomes for cancer patients.
Lantern Pharma (LTRN) announced a collaboration with Code Ocean to enhance its oncology drug discovery efforts using AI. This partnership aims to leverage Code Ocean's Compute Capsule technology to improve the RADR® platform, making research more efficient. The integration focuses on data analysis, collaboration, and reproducibility, potentially reducing costs and development timelines. Lantern Pharma utilizes machine learning to develop therapeutics, currently working on four drug candidates. The collaboration supports partnerships with notable research institutions, optimizing research workflows and productivity.
Code Ocean has partnered with Lantern Pharma (LTRN) to enhance AI-driven computational research for oncology drug discovery. Leveraging Code Ocean's Compute Capsule technology, this collaboration aims to improve efficiency in development time and costs while increasing reproducibility. The integration will help Lantern Pharma utilize its extensive RADR® data points and collaborate effectively with research partners like the National Cancer Institute. This partnership is expected to accelerate the pace of drug discovery by providing a user-friendly and secure research platform.
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, announced it will hold a conference call on November 1, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial and operating results. This conference aims to provide insights into the company's performance and upcoming milestones. Led by CEO Panna Sharma, the management team will also highlight the use of its RADR® A.I. platform for oncology drug discovery. Interested parties can register for the event via the company's website.
Lantern Pharma (LTRN), a clinical-stage biopharmaceutical company, announced its invitation to present at the Fall Harvest - Best Ideas from the Buy-Side conference, scheduled for October 5-8, 2021. CEO Panna Sharma will present on October 6 at 10:00 AM ET. The live webcast will be available for replay after the event. Lantern Pharma leverages its RADR A.I. platform to enhance oncology drug discovery, currently developing four drug candidates across eight tumor targets. Investors can register for the conference and schedule one-on-one meetings.
Lantern Pharma (LTRN) announced a strategic collaboration with Deep Lens, aimed at accelerating patient enrollment for its Phase 2 clinical trial of LP-300 in never-smokers with non-small cell lung cancer (NSCLC). This partnership integrates Deep Lens' VIPER AI platform, enhancing patient matching to clinical trials. Lantern's RADR® AI technology will help identify biomarker signatures for effective oncological therapies. The goal is to streamline the complex drug development process, reduce costs, and improve access to treatments for cancer patients, particularly in the underserved demographic of never-smokers.
Lantern Pharma (NASDAQ: LTRN) announced that President & CEO Panna Sharma will present at the Benzinga Healthcare Small Cap Conference virtually from September 29-30, 2021. Sharma's presentation is scheduled for September 29 at 11:55 AM ET, with one-on-one meetings available throughout the event. Lantern Pharma is focused on oncology drug development, utilizing its proprietary RADR® A.I. platform to identify patients likely to benefit from their genomically targeted therapeutics.
Lantern Pharma (NASDAQ: LTRN) announced participation in two virtual investor conferences in September 2021. Panna Sharma, President & CEO, will host one-on-one meetings at the Colliers Institutional Investor Conference on September 9-10. Additionally, he will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with a presentation available on-demand starting September 13 at 7:00 AM ET. Lantern Pharma leverages its RADR® A.I. platform to discover targeted therapies for oncology, complimented by four drug candidates in development.
FAQ
What is the current stock price of Lantern Pharma (LTRN)?
What is the market cap of Lantern Pharma (LTRN)?
What does Lantern Pharma Inc. specialize in?
What is the RADR platform?
How does Lantern Pharma's approach reduce drug development costs?
What is the company's strategy for growth?
How does Lantern Pharma use AI in drug development?
Who are the key collaborators with Lantern Pharma?
What are some of Lantern Pharma's recent achievements?
Why is precision medicine important in cancer treatment?
How does Lantern Pharma's strategy benefit cancer patients?
What is the significance of biomarker-based genetic screening?
